alvimopan (entereg) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Alvimopan (LY246736, ADL 8-2698, trade name Entereg) is a potent, peripherally selective mu-opioid receptor antagonist. Alvimopan was developed by Adolor Corporation (now Cubist Pharmaceuticals) and GlaxoSmithKline for the treatment of postoperative ileus. Postoperative ileus is the impairment of gastrointestinal motility after intra-abdominal surgery or other non-abdominal surgeries. This may potentially delay gastrointestinal recovery and hospital discharge until its resolution. Morphine and other mu-opioid receptor agonists are universally used for the treatment of acute postsurgical pain; however, they are known to have an inhibitory effect on gastrointestinal motility and may prolong the duration of postoperative ileus. Following oral administration, alvimopan antagonizes the peripheral effects of opioids on gastrointestinal motility and secretion by competitively binding to gastrointestinal tract mu-opioid receptors.   NCATS

Chemistry

  • SMILES: C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C3=CC=CC(O)=C3
  • InChIKey: UPNUIXSCZBYVBB-JVFUWBCBSA-N
  • Mol. Mass: 424.5326
  • ALogP: 3.05
  • ChEMBL Molecule:
    alvimopan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$122.0473 - $134.8720
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

adl 8-2698 | adl8-2698 | alvimopan | alvimopan anhydrous | alvimopan dihydrate | anhydrous alvimopan | entereg | ly246736 | ly 246736 | ly-246736 | trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine

Organizations (20)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Postoperative Complications (approved 2008)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Acute Pain (Phase 4)

Colorectal Surgery (Phase 4)

Constipation (Phase 4)

Fallopian Tube Neoplasms (Phase 3)

General Surgery (Phase 4)

Hamartoma (Phase 3)

Ileus (Phase 4)

Intestinal Diseases (Phase 3)

Intestinal Neoplasms (Phase 4)

Laparoscopy (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 3)

Pain, Postoperative (Phase 4)

Postoperative Complications (Phase 4)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue